A new cellular messenger discovered by Weill Cornell Medicine scientists may help reveal how cancer cells co-opt the body's intercellular delivery service to spread to new locations in the body.
Study by Brazilian researchers shows infection by Zika caused death of cells from glioblastoma, the most common and aggressive kind of malignant brain tumor in adults. Scientists foresee the use of genetic engineering to neutralize Zika virus' infectious whilst preserving the viral particles which induce the death of tumoral cells.
Peptides, short amino acid chains that control many functions in the human body, represent a billion-dollar market, also in the pharmaceutical industry. But, normally these medications must be injected. A research team led by the Technical University of Munich (TUM) has now determined how peptides can be designed so that they can be easily administered as a liquid or tablet.
UZH researchers have discovered a previously unknown way in which proteins interact with one another and cells organize themselves. This new mechanism involves two fully unstructured proteins forming an ultra-high-affinity complex due to their opposite net charge. Proteins usually bind one another as a result of perfectly matching shapes in their three-dimensional structures.
In what is believed to be the largest pancreatic cancer genome-wide association study to date, researchers at the Johns Hopkins Kimmel Cancer Center and the National Cancer Institute, and collaborators from over 80 other institutions worldwide discovered changes to five new regions in the human genome that may increase the risk of pancreatic cancer.
Researchers from Museums Victoria and the University of Melbourne have CT scanned all 13 known Tasmanian tiger joey specimens to create 3-D digital models which have allowed them to study their skeletons and internal organs, and reconstruct their growth and development.
Pediatric and adult cancers with one of three fusion genes responds well to a new drug, larotrectinib, according to a study published today in the New England Journal of Medicine. The drug is designed to target a specific tumor gene mutation known as tropomyosin receptor kinases (TRK) that can occur in various tumor types.
An international team of researchers from NASA Ames Research Center, Environmental and Radiation Health Sciences Directorate at Health Canada, Canadian Nuclear Laboratories, Belgian Nuclear Research Centre, Oxford University, Insilico Medicine, Insilico Medicine Taiwan, the Biogerontology Research Foundation, Boston University, Johns Hopkins University, University of Liverpool, University of Lethbridge, Ghent University, Center for Healthy Aging and many others have published a roadmap toward enhancing human radioresistance for space exploration and colonization.
Three simultaneous safety and efficacy studies of the drug larotrectinib reported an overall response rate of 75 percent for patients ages four months to 76 years with 17 different cancer diagnoses. All patients had tumors with tropomyosin receptor kinase (TRK) fusions, gene mutations that switch on TRK genes, allowing cancer growth. The studies indicate larotrectinib as a potentially powerful new treatment approach for the approximately 5,000 patients with these forms of cancer.
Three quarters of patients, both adults and children, with a variety of advanced cancers occurring in different sites of the body responded to larotrectinib, a novel therapy that targets a specific genetic mutation. Results of a phase 1/2 trial have been published in the New England Journal of Medicine. Unlike most cancer therapies, this oral treatment is based on the genetic traits of the tumor and not the organ where the cancer originated.